



Contact:

David Waldman or Justyna Gudaszewska

Crescendo Communications, LLC

Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)

Tel: +48 693 354 580

### **Milestone Medical Announces F&M Feed as an Exclusive Distributor in Greece and Commences Sales of CompuFlo® Epidural Instrument**

**Roseland, NJ., July 12, 2022 – Milestone Medical Inc. (WAR: MMD, “the Company”)** today signed an exclusive distribution agreement in Greece for the [CompuFlo® Epidural](#) System with F&M Feed, a leading provider of medical equipment, devices and consumables. In connection with the agreement, Milestone Medical has commenced sales and shipments of its CompuFlo Epidural Instrument and consumables to Greece.

Vagelis Epifanis, CEO of F&M Feed, stated, “Our company’s main goal is to find and market innovative products that help to improve people’s lives. The experience of 40 years we have in the field of healthcare gives us the ability to select these products and include them among the products we promote. CompuFlo is a product that will help doctors and patients all over the world. We are very happy about our agreement with Milestone Scientific and look forward to sharing this product in Greece.”

Arjan Haverhals, CEO of Milestone Medical commented, “We are pleased to welcome F&M Feed as our exclusive distribution partner in Greece. We believe that Greece is an important market for us with a population in excess of 10 million people and 76 thousand childbirths each year. F&M Feed has a successful track record launching new medical devices and equipment. The immediate receipt of purchase orders further reinforces our confidence in the market opportunity in this region. We look forward to working closely with F&M Feed in educating medical professionals on the benefits of our system, which provides objective, quantifiable and real-time confirmation when accessing the epidural space.”

#### **About F&M Feed**

Founded in 2013 and certified according to ISO 9001, F&M Feed is a manufacturer and supplier of innovative medical devices and equipment in Greece. The goal of the company is to import, produce and market innovative high-tech products, mitigating the burden on healthcare personnel. For more information, please visit: <https://www.fmfeed.eu>.

#### **About Milestone Medical Inc.**

Milestone Medical, Inc. (WAR:MMD) has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

#### **About Milestone Scientific Inc.**

Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for

medical, dental and cosmetic applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the [MLSS brand video](#) or visit [milestonescientific.com](http://milestonescientific.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2021. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*